Chadi hosts Dr. Neal Shore, a urologic oncologist who became heavily involved in GU oncology research – including trials that incorporate systemic chemotherapy. Dr. Shore has a unique practice where he and his staff deliver chemotherapy when appropriate. Chadi was intrigued by this setting as medical oncologists are the ones customarily delivering chemotherapy, and invited him to the show to share how this all started, its pros and cons, and the impact on patients.
Dr. Shore explains how the field has seen drastic changes since the early 1990’s, why he decided to spearhead bringing clinical research into his community clinic, and how his clinic is staffed and structured to support a functioning and successful research hub. Then, the discussion pivots to his recently published clinical trial, ENACT, and the controversy surrounding use of enzalutamide monotherapy in low- or intermediate-risk prostate cancer. There’s been so much controversy and backlash about the ENACT trial that Chadi had to ask him about it and his reaction to what happened when the article was published.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
